Serveur d'exploration sur Heinrich Schütz

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

IL-6 signal transduction and its physiological roles: the signal orchestration model

Identifieur interne : 000901 ( Main/Exploration ); précédent : 000900; suivant : 000902

IL-6 signal transduction and its physiological roles: the signal orchestration model

Auteurs : D. Kamimura [Japon] ; K. Ishihara [Japon] ; T. Hirano [Japon]

Source :

RBID : ISTEX:E476EA2C956E949A5D7F514ACA1BF3F61A2ABC1D

Abstract

Abstract: Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.


Url:
DOI: 10.1007/s10254-003-0012-2


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">IL-6 signal transduction and its physiological roles: the signal orchestration model</title>
<author>
<name sortKey="Kamimura, D" sort="Kamimura, D" uniqKey="Kamimura D" first="D." last="Kamimura">D. Kamimura</name>
</author>
<author>
<name sortKey="Ishihara, K" sort="Ishihara, K" uniqKey="Ishihara K" first="K." last="Ishihara">K. Ishihara</name>
</author>
<author>
<name sortKey="Hirano, T" sort="Hirano, T" uniqKey="Hirano T" first="T." last="Hirano">T. Hirano</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E476EA2C956E949A5D7F514ACA1BF3F61A2ABC1D</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1007/s10254-003-0012-2</idno>
<idno type="url">https://api.istex.fr/document/E476EA2C956E949A5D7F514ACA1BF3F61A2ABC1D/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">001213</idno>
<idno type="wicri:Area/Main/Curation">001201</idno>
<idno type="wicri:Area/Main/Exploration">000901</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">IL-6 signal transduction and its physiological roles: the signal orchestration model</title>
<author>
<name sortKey="Kamimura, D" sort="Kamimura, D" uniqKey="Kamimura D" first="D." last="Kamimura">D. Kamimura</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Molecular Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka</wicri:regionArea>
<wicri:noRegion>Osaka</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ishihara, K" sort="Ishihara, K" uniqKey="Ishihara K" first="K." last="Ishihara">K. Ishihara</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Molecular Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka</wicri:regionArea>
<wicri:noRegion>Osaka</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory of Developmental Immunology, Graduate School of Frontier Biosciences, Osaka University, Osaka</wicri:regionArea>
<wicri:noRegion>Osaka</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hirano, T" sort="Hirano, T" uniqKey="Hirano T" first="T." last="Hirano">T. Hirano</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Molecular Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka</wicri:regionArea>
<wicri:noRegion>Osaka</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory of Developmental Immunology, Graduate School of Frontier Biosciences, Osaka University, Osaka</wicri:regionArea>
<wicri:noRegion>Osaka</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology, Yokohama</wicri:regionArea>
<wicri:noRegion>Yokohama</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Japon</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="s">Reviews of Physiology, Biochemistry and Pharmacology</title>
<imprint>
<date>2004</date>
</imprint>
<idno type="ISSN">0303-4240</idno>
<idno type="ISSN">0303-4240</idno>
</series>
<idno type="istex">E476EA2C956E949A5D7F514ACA1BF3F61A2ABC1D</idno>
<idno type="DOI">10.1007/s10254-003-0012-2</idno>
<idno type="ChapterID">Chap1</idno>
<idno type="ChapterID">1</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0303-4240</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Japon</li>
</country>
</list>
<tree>
<country name="Japon">
<noRegion>
<name sortKey="Kamimura, D" sort="Kamimura, D" uniqKey="Kamimura D" first="D." last="Kamimura">D. Kamimura</name>
</noRegion>
<name sortKey="Hirano, T" sort="Hirano, T" uniqKey="Hirano T" first="T." last="Hirano">T. Hirano</name>
<name sortKey="Hirano, T" sort="Hirano, T" uniqKey="Hirano T" first="T." last="Hirano">T. Hirano</name>
<name sortKey="Hirano, T" sort="Hirano, T" uniqKey="Hirano T" first="T." last="Hirano">T. Hirano</name>
<name sortKey="Hirano, T" sort="Hirano, T" uniqKey="Hirano T" first="T." last="Hirano">T. Hirano</name>
<name sortKey="Ishihara, K" sort="Ishihara, K" uniqKey="Ishihara K" first="K." last="Ishihara">K. Ishihara</name>
<name sortKey="Ishihara, K" sort="Ishihara, K" uniqKey="Ishihara K" first="K." last="Ishihara">K. Ishihara</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/corpus/SchutzV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000901 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    SchutzV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E476EA2C956E949A5D7F514ACA1BF3F61A2ABC1D
   |texte=   IL-6 signal transduction and its physiological roles: the signal orchestration model
}}

Wicri

This area was generated with Dilib version V0.6.20.
Data generation: Sun Apr 10 01:23:10 2016. Site generation: Fri Aug 18 21:45:27 2017